Biotech firm Atox Bio Ltd. and contract research organization Fast-Track Drugs & Biologics LLC, together received $575,000 from the Israel-United States Binational Industrial Research and Development Foundation (BIRD-F) for development of a sepsis treatment. The program will fund pre-clinical trial research and a Phase I clinical trial. The clinical trial will be conducted at the Univesity of Maryland. RELATED ARTICLES Yissum turns to private equity for funding The joint program will continue the development of Atox Bio's novel peptide, AB103, for the treatment of sepsis and septic shock. The treatment is based on research of Atox's two co-founders, chief scientist Dr. Raymond Kaempfer and director of R&D Dr. Gila Arad. Atox is a holding of Yissum Technology Transfer Company of the Hebrew University of Jerusalem. Published by Globes [online], Israel business news - www.globes-online.com - on June 28, 2009 © Copyright of Globes Publisher Itonut (1983) Ltd. 2009